艾曲波帕联合重组人血小板生成素治疗难治性血小板减少性紫癜的疗效分析  

Efficacy Analysis of Atratropin Combined with Recombinant Human Thrombopoietin in the Treatment of Refractory Thrombocytopenic Purpura

作　　者：顾小慧 赵凤晓 尹淑荣 GU Xiao-hui;ZHAO Feng-xiao;YIN Shu-rong(Department of Hematology,Second People's Hospital of Qujing City,Qujing,Yunnan Province,655000 China)

机构地区：[1]曲靖市第二人民医院血液肿瘤科,云南曲靖655000

出　　处：《中外医疗》2020年第2期101-103,共3页China & Foreign Medical Treatment

摘　　要：目的研究艾曲波帕联合重组人血小板生成素治疗难治性血小板减少性紫癜的疗效。方法方便选取2017年1月—2018年12月于该院诊断治疗的难治性血小板减少性紫癜患者36例。将患者随机分为观察组和对照组,每组18例。对照组采用重组人血小板生成素等基础药物进行常规治疗,观察组患者在对照组治疗方式的基础上采用艾曲波帕进行联合治疗。治疗观察3个月后,统计分析患者临床症状改善情况、不良反应发生情况以及血小板改善情况。结果治疗后,观察组患者治疗效果(94.44%)明显优于对照组(66.67%),两组比较差异有统计学意义(χ^2=4.434,P<0.05);观察组患者治疗7 d后(58.7±14.1)10^9/L、30 d后(70.7±21.1)10^9/L血小板水平改善情况好于对照组,两组比较差异有统计学意义(t=2.098、2.067,P<0.05)。结论艾曲波帕联合重组人血小板生成素可有效治疗难治性血小板减少性紫癜,提高患者血小板水平,且联合用药后,不良反应未见明显升高,值得临床进一步研究推广。Objective To study the efficacy of Eltrombopag combined with recombinant human thrombopoietin in the treatment of refractory thrombocytopenic purpura.Methods Convenient select 36 patients with refractory thrombocytopenic purpura who were diagnosed and treated in the hospital from January 2017 to December 2018 were enrolled.Patients were randomly divided into observation group and control group,with 18 cases in each group.The control group was treated with conventional drugs such as recombinant human thrombopoietin,and the patients in the observation group were treated with a combination of Eltrombopag on the basis of the treatment mode of the control group.Three months after treatment and observation,the patients were statistically analyzed for improvement in clinical symptoms,adverse reactions,and improvement in platelets.Results After treatment,the therapeutic effect of the observation group(94.44%)was significantly better than that of the control group(66.67%).The difference between the two groups was statistically significant(χ^2=4.434,P<0.05);the observation group was treated for 7 days(58.7±14.1)×10^9/L,30 days(70.7±21.1)×10^9/L,the improvement of platelet level was better than that of the control group.The difference between the two groups was statistically significant(t=2.098,2.067,P<0.05).Conclusion Eltrombopag combined with recombinant human thrombopoietin can effectively treat refractory thrombocytopenic purpura and improve the platelet level of patients.After combined use,the adverse reactions have not increased significantly,which is worthy of further clinical research and promotion.

关 键 词：艾曲波帕 重组人血小板生成素 难治性血小板减少性紫癜 临床疗效 

分 类 号：R554.6[医药卫生—血液循环系统疾病]